



CBD MED RESEARCH CORP

#810 – 675 W. Hastings Street, Vancouver, B.C., Canada V6B 1N2
Tel: 604-802-7551 • www.cbdmedresearch.com

December 2, 2015

CBD MED RESEARCH CORP. ("CBM" or the "Company")

TSX.V NEX Symbol: CBM.H

CBD MED RESEARCH CORP. – EXCLUSIVE MEDICAL INFUSION TECHNOLOGY DISTRIBUTION RIGHTS

December 2, 2015, - CBD MED Research Corp. (“THE COMPANY”) is pleased to announce that a **“definitive agreement”** for exclusive Canadian Distribution Rights has been signed by the parties CBD Med Research Corp. and Medipacs Inc. Medipacs is a private wearable infusion pump technology company based in San Diego, California. To view the award winning technology go to www.medipacs.com.

Medipacs’ novel technology (only one moving part) provides a wearable, lightweight, small (size of small cell phone), disposable pump with digital capabilities. The Medipacs pump delivers precise pain medication therapies for animal healthcare as well as for human use in the near future.

BENEFITS of The Medipacs Pump

- High performance, scalable, thin and wearable pumps with high precision that, can deliver medications over days.
- Provides continuous delivery of medication at the prescribed dose
- Multiple injections could potentially be eliminated
- IV access is not needed. Medications can be administered via subcutaneous cannula
- Patients are not tethered to an IV pump therefore increasing mobility of the patient
- Less medication may be used with fewer side effects
- Assist in the reduction of medication preparation errors and IV infections
- Wireless capability for programming/monitoring
- Provides potential reduction in health care costs

Medipacs Inc. has invested \$12 million dollars in the development of its novel infusion technology with 33 patents filed and 8 issued on its unique polymer technology and pump systems.

The Medipacs wearable **Mini-Infuser™ CRI (Continuous Rate Infuser) Pump** represents a new class for injectable medication delivery systems. The patented process allows for a small, lightweight, wearable, Mini-Infuser™ Pump to deliver personalized medicine solutions to humans and animals.

Mini-Infuser™ CRI Pump, Product Rollout

Commercial Marketing of the Mini-Infuser™ CRI Pump to the Veterinary surgical market in Canada is expected to commence in the second quarter of 2016, (Medipacs will lead the product launch in the USA during the first quarter of 2016)

CBD and Medipacs Market Preparation and Product Launch will engage and target:

- Compounding pharmacy animal health care partnerships
- Veterinary market distribution agreements
- Co-op veterinary organization marketing
- Demonstrations to veterinary surgical clinics
- Introductions to veterinary surgical clinics – direct sales
- Introductions to high profile veterinary institutions and key opinion leaders

Compounding pharmacies will formulate and mix specialty medications to best suit each client veterinary clinic animal health needs. The **Mini-Infuser™ CRI Pump** design allows the compounding pharmacies to custom formulate and pre-fill the precision pumps with the required formulation. The custom-filled prescription may be delivered directly to the veterinarian for administration.

The Mini-Infuser™ CRI Pump is a wearable, single use and disposable. The pump can be programmed to meet the individual needs of the veterinarian and patient for each clinical situation. The current use is for pain management in canines.

The Mini-Infuser™ CRI Pump is intended to allow selection of infusion rate of a medication of choice loaded into the pump by the Veterinary pharmacy or technician.

The (human) PRN Pump: Medipacs anticipates FDA clearance for the human pump and product launch in 2017.

Scientific advisory and Business Development Advisors

To assist CBD Management and Board of Directors, the Company previously assembled a very active and experienced team of medical technology and business advisors comprising of:

Dr. Bill Cheliak, Dr. Charles Garrison, Dr. Gianni Maddalozzo, Dr. Roman Dvorak, Mr. Brian T. Wagner and Mr. John McCluskey

Gary F. Zak, CEO, stated, “The Management and Board is very excited to prepare a coordinated country wide launch of this ground breaking new medical technology.

On behalf of the Board of Directors,

CBD Med Research Corp.

"Gary F. Zak"

President, CEO

Email: gzak1@shaw.ca

Tel: 604-802-7551

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes certain statements that may be deemed “forward-looking statements”. For more information on the Company and the risks and challenges of its business, investors should review the Company’s annual filings that are available at www.sedar.com